Home / Oligonucleotides and Peptides / Discovery / Peptide

Peptide CRDMO Services

Delivering the precision and expertise your peptides therapy requires to reach the patients who need it.

Large-Scale Peptide CRDMO, Built for Speed and Reliability

WuXi TIDES delivers one of the industry’s largest and most scalable peptide CRDMO platforms, supporting peptide programs from discovery through commercial manufacturing. Built on extensive solid-phase peptide synthesis capacity and integrated development, analytical, and GMP manufacturing capabilities, our peptide services are designed to help programs advance efficiently as complexity and material demand increase.

Industry-Leading Peptide Manufacturing Capacity

Capacity is not just scale—it determines whether a peptide program can transition smoothly from early development into late-stage and commercial supply.

WuXi TIDES operates over 100,000 L of solid-phase peptide synthesis (SPPS) capacity, enabling reliable support for peptides ranging from early material needs to multi-kilogram and commercial production. This large-scale infrastructure allows clients to avoid platform changes as programs advance, reducing tech transfer risk and ensuring continuity across development stages.

API Manufacturing

Handling Complex and High-Demand Peptide Modalities

Modern peptide pipelines increasingly involve long sequences, modified residues, conjugation handles, and high-potency profiles. WuXi TIDES supports a broad range of peptide formats, including linear, cyclic, modified, and conjugation-ready peptides, with infrastructure and containment systems appropriate for high-potency and complex products.

This breadth allows clients to progress innovative peptide candidates without needing to fragment development across multiple vendors.

Peptide-Based Conjugates